Literature DB >> 29112020

Distinguishing Neurofibroma From Desmoplastic Melanoma: The Value of p53.

Ashley Elsensohn1, Jessica Shiu1, Narina Grove2, Anna-Marie Hosking1, Ronald Barr3, Sébastien de Feraudy1.   

Abstract

Distinguishing desmoplastic melanomas (DMs) from neurofibromas (NFs) can be histologically challenging in some cases. To date, a reliable marker to differentiate the 2 entities has remained elusive. S100 subtyping and CD34 fingerprinting have been proposed, but controversy remains as to their reliability. Missense mutations in TP53 are often found in DMs, resulting in a dominant negative effect and paradoxical accumulation of the tumor suppressor protein p53. We hypothesized that p53 may be expressed differentially in DMs, making it a valuable tool in differentiating DMs from NFs. Using immunohistochemistry, we compared p53 protein expression in 20 DMs and 20 NFs retrieved from our tissue archives and stained with p53 antibody (Monoclonal, DO-7). Patients with DM included 18 men and 2 women (age, 36 to 95 y; mean, 70.5 y; median, 70 y). Fifteen (15/20) tumors occurred in head and neck area; 2 (2/20) on the trunk; and 3 (3/20) on the extremities. Patients with NF included 12 men and 8 women (age, 47 to 85 y; mean, 65.2 y; median, 69.5 y). Eleven (11/20) tumors occurred on the trunk, 6 (6/20) on the extremities, and 3 (3/20) on the head and neck area. A total of 19/20 (95%) DMs were positive for p53. DM Histo-scores ranged from 0 to 300 (mean, 203; median, 260). Nuclear accumulation of p53 was seen in all 19 positive DMs. None of the 20 NFs were positive for p53 (2-tailed t test P-value <0.0001). Detection of p53 by immunohistochemistry can help to distinguish DMs from NFs.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29112020      PMCID: PMC6095644          DOI: 10.1097/PAS.0000000000000978

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  15 in total

1.  Fingerprint CD34 immunopositivity to distinguish neurofibroma from an early/paucicellular desmoplastic melanoma can be misleading.

Authors:  Sameera Husain; David N Silvers
Journal:  J Cutan Pathol       Date:  2013-08-27       Impact factor: 1.587

2.  Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma).

Authors:  J Conley; R Lattes; W Orr
Journal:  Cancer       Date:  1971-10       Impact factor: 6.860

3.  Desmoplastic melanoma with sarcomatoid dedifferentiation.

Authors:  Maija Kiuru; Gregory McDermott; Michael Berger; Allan C Halpern; Klaus J Busam
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

4.  NF1 Mutations Are Common in Desmoplastic Melanoma.

Authors:  Thomas Wiesner; Maija Kiuru; Sasinya N Scott; Maria Arcila; Allan C Halpern; Travis Hollmann; Michael F Berger; Klaus J Busam
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

5.  Allelic loss at the neurofibromatosis type 1 (NF1) gene locus is frequent in desmoplastic neurotropic melanoma.

Authors:  R Gutzmer; R A Herbst; S Mommert; P Kiehl; F Matiaske; A Rütten; A Kapp; J Weiss
Journal:  Hum Genet       Date:  2000-10       Impact factor: 4.132

6.  Absence of V599E BRAF mutations in desmoplastic melanomas.

Authors:  Jon M Davison; Eli Rosenbaum; Terry L Barrett; David Goldenberg; Mohammad O Hoque; David Sidransky; William H Westra
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

7.  Differential expression of S100 protein subtypes in malignant melanoma, and benign and malignant peripheral nerve sheath tumors.

Authors:  Daisuke Nonaka; Luis Chiriboga; Brian P Rubin
Journal:  J Cutan Pathol       Date:  2008-06-10       Impact factor: 1.587

8.  Expression of p53 protein in malignant melanoma: clinicopathological and prognostic implications.

Authors:  J Weiss; M Heine; B Körner; H Pilch; E G Jung
Journal:  Br J Dermatol       Date:  1995-07       Impact factor: 9.302

9.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

Authors:  Fred R Hirsch; Marileila Varella-Garcia; Paul A Bunn; Michael V Di Maria; Robert Veve; Roy M Bremmes; Anna E Barón; Chan Zeng; Wilbur A Franklin
Journal:  J Clin Oncol       Date:  2003-09-02       Impact factor: 44.544

10.  Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway.

Authors:  A Hunter Shain; Maria Garrido; Thomas Botton; Eric Talevich; Iwei Yeh; J Zachary Sanborn; Jongsuk Chung; Nicholas J Wang; Hojabr Kakavand; Graham J Mann; John F Thompson; Thomas Wiesner; Ritu Roy; Adam B Olshen; Alexander Gagnon; Joe W Gray; Nam Huh; Joe S Hur; Klaus J Busam; Richard A Scolyer; Raymond J Cho; Rajmohan Murali; Boris C Bastian
Journal:  Nat Genet       Date:  2015-09-07       Impact factor: 38.330

View more
  4 in total

Review 1.  What's new in nerve sheath tumors.

Authors:  Anders Meyer; Steven D Billings
Journal:  Virchows Arch       Date:  2019-11-09       Impact factor: 4.064

2.  Diffuse Neurofibroma: An Uncommon Cause of Alopecia.

Authors:  I-Ting Lee; Jian-Min Chang; Yu Fu
Journal:  Skin Appendage Disord       Date:  2020-02-27

3.  Non-disruptive mutation in TP53 DNA-binding domain is a beneficial factor of esophageal squamous cell carcinoma.

Authors:  Minran Huang; Jiaoyue Jin; Fanrong Zhang; Yingxue Wu; Chenyang Xu; Lisha Ying; Dan Su
Journal:  Ann Transl Med       Date:  2020-03

4.  Desmoplastic Melanoma: A Clinicopathological Analysis of Three Cases in the Chinese Population.

Authors:  Yaqi Fan; Mingyuan Xu; Yulin Liang; Nanhui Wu; Feiyan Wang; Qian Du; Yun Bai; Yeqiang Liu
Journal:  Onco Targets Ther       Date:  2021-04-15       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.